PS
NAMS icon

Principal Securities’s NewAmsterdam Pharma NAMS Stock Holding History

Principal Securities’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13
Closed -$334 – 3817
2025
Q1 		$334 Hold
13
– – ﹤0.01% 3409
2024
Q4 		$334 Sell
13
-10
-43% -$212 ﹤0.01% 3404
2024
Q3 		$382 Buy
23
+18
+360% +$311 ﹤0.01% 3311
2024
Q2 		$96 Hold
5
– – ﹤0.01% 3362
2024
Q1 		$118 Buy
+5
New +$101 ﹤0.01% 3277

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Principal Securities's NAMS Position: Q2 2025 in Review

Principal Securities sold out of NewAmsterdam Pharma (NAMS) in Q2 2025, closing a stake of 13 shares — an estimated $334 sold.

Principal Securities first reported a position in NAMS in Q1 2024 and held it in 5 quarters. The position peaked at $382 in Q3 2024. 131 funds tracked by Wall St. Rank hold NAMS as of Q2 2025.

  • Principal Securities reported no remaining NewAmsterdam Pharma position as of Q2 2025 after selling out during the quarter.
  • Principal Securities sold 13 NewAmsterdam Pharma shares in Q2 2025, an estimated $334.
  • Principal Securities first reported a position in NewAmsterdam Pharma in Q1 2024 and held it in 5 quarters.
  • Principal Securities's NewAmsterdam Pharma position peaked at $382 in Q3 2024.
  • 131 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2025.

Based on Principal Securities's 13F filing for Q2 2025, filed 11 Aug 2025.